クイザルチニブと化学療法によるFLT3内部複製陽性急性骨髄性白血病 (QuANTUM- First) の新規診断患者によるランダム化,ダブルブラインド,プラセボ対照,第3相試験
PubMedで要約を見る
まとめ
この要約は機械生成です。クイザルチニブは,FLT3- ITD変異の新規診断された急性骨髄性白血病 (AML) 患者における全生存率を有意に改善しました. この標的治療は,この高リスクAMLサブグループに対して,新しい,よく許容される治療の選択肢を提供します.
科学分野
- 血液学
- 腫瘍学
- 臨床試験
背景
- FLT3 内部タンデム複製 (ITD) 変異による急性骨髄性白血病 (AML) は,患者の悪影響と関連しています.
- クイザルチニブは,FLT3陽性AMLにおける抗腫瘍活性を示す強力な選択性FLT3阻害剤である.
研究 の 目的
- 新規診断のFLT3- ITD陽性AML患者における全生存率の改善におけるキザルチニブと化学療法とプラセボの効果を比較する.
主な方法
- ランダム化,ダブルブラインド,プラセボ制御のフェーズ3試験 (QuANTUM- First) で,26カ国の539人の患者が参加した.
- 患者は,キザルチニブまたはプラセボによる誘導および整合化学療法を受け,その後,最大3年間の単剤継続療法を受けた.
- 主要エンドポイントは全生存期であり,すべての被験者の安全性が評価された.
主要な成果
- プラセボ群 (15. 1ヶ月) と比較して,キザルチニブ群の全生存期間の中央値は有意に長かった (HR 0. 78, p=0. 032).
- 発熱性ニュートロペニアと肺炎を含むグレード3/4の有害事象の発生率はグループ間で類似した.
- クイザルチニブは,標準化学療法に追加されたとき,許容可能な安全性プロファイルを示した.
結論
- 標準化学療法にキザルチニブを追加すると,新たに診断されたFLT3- ITD陽性AMLの成人の全生存率が著しく改善されます.
- クイザルチニブは,この患者集団にとって,新しい,有効で,一般的によく耐える治療法です.
関連する概念動画
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

